We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Liquid Biopsy Assay Predicts if Esophageal Cancer Patients Will Respond to Treatment

By LabMedica International staff writers
Posted on 17 Jun 2022
Print article
Image: A liquid biopsy can determine if a patient with esophageal cancer will respond to certain treatments (Photo courtesy of Pexels)
Image: A liquid biopsy can determine if a patient with esophageal cancer will respond to certain treatments (Photo courtesy of Pexels)

Biomarkers are like the X on a treasure map, but instead of indicating the location of unearthed riches, they indicate an individual’s health status. Common biomarkers include certain RNA or protein molecules present in tissues and body fluids that can show doctors that a patient has a specific disease or may respond well to a particular treatment plan. Liquid biopsies are appealing as a non-invasive method for measuring biomarker levels in a body fluid. A team of researchers has now designed such a method for predicting patient outcomes following treatment for esophageal squamous cell carcinoma (ESCC), an aggressive and deadly disease.

Surgery is the typical treatment method for ESCC, but recent research has shown that adding neoadjuvant therapy (NAT) can improve patient survival rates. NAT involves shrinking a tumor using approaches such as chemotherapy or radiation prior to surgery. However, not all patients are responsive to NAT. Unnecessarily performing it can take time for these patients and lead to worse outcomes. Therefore, the team of researchers from Tokyo Medical and Dental University (TMDU, Tokyo, Japan) aimed to identify biomarkers and characteristics that could preemptively indicate an ESCC patient’s response to NAT.

To do this, the team obtained 128 ESCC tissue samples and 58 matched serum samples from two clinical institutions. The serum was obtained prior to any treatment. NAT for these patients involved chemotherapy with 5-fluorouracil and cisplatin, followed by surgery 3 to 5 weeks later. Pathologists then analyzed the surgical specimens for residual tumor cells, which helped them categorize these ESCC patients as completely, partially, or non-responsive to NAT.

After the researchers analyzed their data, they concluded that their panel of mRNAs and microRNAs had significant predictive potential. Interestingly, combining the panel with tumor size data further increased the predictive power. mRNA/microRNA signature was the most effective clinical characteristic amongst various combinations. It worked in both early- and advanced-stage ESCC patients. Overall, the liquid biopsy developed by the researchers may serve as a non-invasive method for predicting ESCC patient response to NAT. This can lead to precision medicine approaches that will significantly improve the prognosis of many patients who have this disease.

“Molecular biomarkers can be extremely useful when making clinical decisions,” said lead author of the study Keisuke Okuno. “We also wanted to translate these biomarkers into an easy-to-use liquid biopsy.

“We then examined these patient samples for expression levels of molecules that included three mRNAs and four microRNAs,” added Ajay Goel, senior author of the article. “In previous studies, this panel of mRNAs and microRNAs was found to effectively predict ESCC patient response to NAT.”

“We then utilized the pre-treatment serum samples to translate this signature into a liquid biopsy assay, and our approach still maintained its strong ability to predict response to NAT,” explained Okuno.

Related Links:
TMDU 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.